Immuno-oncology (I-O) is the leading field with many groundbreaking discoveries in immunology and cancer therapy in the last century involving manipulation of immune checkpoints. I-O therapies stimulate the body’s immune system to target and attack the tumor, which is otherwise invisible to, or inhibiting the immune response. Programmed cell death protein 1 (PD-1)/PD-L1 inhibitors have been successful as a drug following CTLA4 inhibitor (ipilimumab). Pembrolizumab (Keytruda) is a fully humanized antibody targeted against the PD-1 receptor. FDA approval was fast tracked after it was deemed a breakthrough therapy based on results of a phase IB study for treatment of metastatic unresectable melanoma. Nivolumab (Opdivo) is another fully humanized antibody directed against the PD-1 receptor. Similar to pembrolizumab, it was granted accelerated approval by the FDA in 2014 for the treatment of metastatic or unresectable melanoma unresponsive to ipilimumab or BRAF inhibitors. In 2015, it was also approved for metastatic squamous NSCLC unresponsive to platinum-based chemotherapy. Pembrolizumab and nivolumab are often options employed in patients unresponsive to ipilimumab. Atezolizumab (Tecentriq) was the first FDA approved drug among the class of PD-L1 inhibitors implicated for the targeted treatment of bladder cancer. Some other drugs in this class including MEDI4736 (AstraZeneca), MPDL3280A (Roche), MSB0010718C (Merck) have shown promising results in Phase I trials of NSCLC patients. Since 2011, owing to its potential for a large and sustained clinical benefit, immuno-oncology has become the fastest-growing area not only in oncology but in the entire pharmaceutical industry.
The global programmed cell death protein 1 (PD-1)/PD-L1 inhibitors market segmentation is based on drug type (brand) – atezolizumab (Tecentriq, MPDL3280A), avelumab (Bavencio, MSB0010718C), durvalumab (Imfinzi, MEDI4736), nivolumab (Opdivo), pembrolizumab (Keytruda).
The global programmed cell death protein 1 (PD-1)/PD-L1 inhibitors market research report provides market size (Revenue US$ Million 2014 to 2025), market share analysis, growth trends and forecast (CAGR%, 2017 to 2025). The global programmed cell death protein 1 (PD-1)/PD-L1 inhibitors market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global programmed cell death protein 1 (PD-1)/PD-L1 inhibitors market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global programmed cell death protein 1 (PD-1)/PD-L1 inhibitors market and profiled in this report include Amgen, Astex Pharmaceuticals (Otsuka Pharmaceuticals), AstraZeneca (MedImmune), Bristol-Myers Squibb Company, Celgene, CureTech, Debiopharm, Elli Lilly, F. Hoffmann-La Roche Ltd. (Genentech), GlaxoSmithKline, Immunocore, Juno Pharmaceuticals, Kite Pharma, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceutical, Inc., Seattle Genetics, Syndax Pharmaceuticals, and Verastem.